FOR weeks, speculation has been rife that Pfizer, the world's biggest pharmaceuticals company, will break itself into pieces, a restructuring move known as the starburst.
数周来，关于全球最大的制药企业辉瑞公司，将会采取星爆式重组的方式进行拆分的猜测不绝于耳。
Even traditionally defensive industries, such as pharmaceuticals, are suffering: Pfizer plans to lay off up to 8% of its researchers.
即使是比较保守性的行业，如制药业也深受其害：辉瑞公司计划解雇高达总雇员8%的研究员。
And on December 4th Pfizer, the pharmaceuticals giant, saw its share price plunge after yet another drug failed the testing process (see article).
12月4日，在医药品巨头的另外一种药品未能通过测试程序后，它见证了自己股票价格的大跳水。
Pfizer last week announced a deal with Canadian biotech Tekmira Pharmaceuticals Corp for this type of delivery vehicle for its RNAi drugs, joining Roche and Alnylam.
辉瑞公司上周宣布，已与罗氏和Alnylam一道，就这种形式的RNAi药物运输工具与加拿大生物技术Tekmira制药公司达成一笔交易。
Pfizer agreed to buy King Pharmaceuticals, a maker of pain remedies, for $3.6 billion.
辉瑞制药公司将以36亿美元协议收购君王制药公司，该公司主要生产止痛药。
Pfizer agreed to buy King Pharmaceuticals, a maker of pain remedies, for $3.6 billion.
辉瑞制药公司将以36亿美元协议收购君王制药公司，该公司主要生产止痛药。
应用推荐